Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.49 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29293219 | 0.87 | TAAR1 (0.49) | TAAR1HTR6ADRA2AADRA2BADRA2C | |
| SCHEMBL4996903 | 0.73 | TAAR1 (0.60) | TAAR1HTR6ADRA2AADRA2BADRA2C | |
| SCHEMBL29293325 | 0.69 | PLA2G1B (0.33) | TAAR1SLC6A4 | |
| SCHEMBL29293271 | 0.67 | KCNH2 (0.36) | SLC6A4 | |
| SCHEMBL14516395 | 0.67 | SLC6A4 (0.44) | SLC6A4HTR2A | |
| SCHEMBL3056908 | 0.66 | TAAR1 (1.00) | TAAR1HTR7AOC3 | |
| SCHEMBL27366111 | 0.66 | HTR2A (0.64) | TAAR1HTR6ADRA2AADRA2BADRA2C | |
| SCHEMBL25380394 | 0.65 | SLC6A4 (0.83) | HTR6ADRA2AADRA2BADRA2CHTR7 | |
| SCHEMBL7854851 | 0.65 | SLC6A4 (0.83) | HTR6HTR7HTR2BSLC6A4HTR2A | |
| Hydrochloric Acid SCHEMBL8507687 | 0.65 | TAAR1 (0.96) | TAAR1HTR7AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |